pharmaceuticals-and-healthcare

2012-2022 Report on Global CRISPR Market Competition, Status and Forecast, Market Size by Players, Regions, Type, Application


Published On : Apr 2017

Category : Biotechnology

No. of Pages : 104 pages

  • $3668
  • $7336

Please click below to avail discount on this report

The Global CRISPR Market is expected to grow from $XXX million in 2016 and CAGR XX% for the forecasted period of 2017-2022. The gene editing technology has grown significantly in the last decade. The gene editing tools have become more accessible and cost effective which has enabled a thorough understanding of human genome. CRISPR (clustered regularly interspaced short palindromic repeats) is a new gene editing tool which has opened new doors for gene editing. This technology allows researchers to perform microsurgery on genes, precisely and easily, changing a DNA sequence at exact locations on a chromosome. The global market of CRISPR is expected to grow from $XX million in 2016 and CAGR XX% for the forecasted period of 2017-2022.

CRISPR market is expected to grow on the back of several drivers such as increased R&D expenditure on biotechnology, backed by venture capitals, increasing age related genetic disorders, increasing private and government expenditure on genetic research, high prevalence rate of genetic birth disorders and high demand of synthetic genes. Several factors such as limited awareness and little presence in emerging markets are restraints in the path of growth of the market.

The Global CRISPR market is segmented on the basis of application and end users: On the basis of application the market is segmented into Genome Editing, Genetic engineering, gRNA Database/Gene Library, CRISPR Plasmid and vectors so on. CRISPR Plasmid is the highest growing segment due to high demand among scientists and researchers. By end user, the market is segmented into Biotechnology companies, Pharmaceutical companies, Academic and research Institutes, Research and development institutes, Competitive Intelligence, Merger and Acquisitions and Innovation. In end user, the academic and research is highest growing segment due to high level of R&D into genome process, development of new drugs and development of genetically modified organisms and drugs.

The geography analysis consists of North America (US, Canada), Europe (United Kingdom, France, Germany, Spain, Italy), Asia Pacific (India, China, Japan) and Rest of the world. North America is the largest geographical market (2016) in CRISPR because high level of academies and research based in region. Asia-Pacific region is expected to grow at the fastest rate in forecasted period due to increase in number of contract research organization and emergence of drug discovery.

Major industry players in CRISPR market are: Editas Medicine (US), CRISPR therapeutics (Switzerland), GenScript USA Inc. (US), Horizon Discovery Group plc (UK), Integrated DNA Technologies, Inc. (US), Lonza Group Ltd. (Switzerland), New England Biolabs, Inc. (US), OriGene Technologies, Inc. (US), Sangamo Biosciences, Inc. (US), Sigma-Aldrich Corporation (US), Thermo Fisher Scientific, Inc. (US), Transposagen Biopharmaceuticals (US), Santa Cruz Biotechnology (US), Dharmacon (US), ZGene Biotech (TW), Blue Heron Bio (US), Takara Bio (JP), Synthego (US), Mirus Bio (US), Agilent Technologies (US), VCANBIO Cell & Gene Engineering (CN), Shenzhen Jinjia Group (CN), Galaxy Biomed (CN), Tofflon (CN), AOYANG Group (CN), ANKEBIO (CN).

A massive portion of the overall impetus that players and markets associated with biotechnology are receiving, comes from the rapidly increasing government support. Developed economies are especially ahead of the game in terms of research and development, as well as the incorporation of ready products into the commercial markets. However, it should be noted that the average time to market for a standard biotechnology product is exceedingly higher than conventional medical products. Despite this, players are becoming ever ready to tackle the more promising fields in biotechnology, namely stem cell technology, nanotechnology, and genetic cloning. This field is poised to be an inseparable part of the healthcare industry, and is in need of heavy efforts on the research and development side.

The 2012 2022 report on global crispr market competition status and forecast market size by players regions type application is a very different market loaded with exceptional competitors and very specific customer and end user appeals. The improvement of innovations is additionally in high demand, with the developed economies demonstrating a more prominent consideration in the advancement of cutting edge advances than the developing economies. The report considers every such element while surveying the upcoming expected openings for players in the market over the coming years. It therefore converts the data presented into a matter of point of view, and offers the most ideal one for the market as far as getting favored by the key drivers and patterns influencing the market is concerned, while evading the hindrances that could prevent the advance of the players. The establishment for this investigation is made by getting the readers of this report familiar with the basic syntax of the market as it is important to completely comprehend its progression that the said entities are expected to promote themselves on.

The regional examination of the 2012 2022 report on global crispr market competition status and forecast market size by players regions type application can be depicted as a widely inclusive survey of the key locations, from the points of view of these locations as specified through their existing player base and the general end user reports for them. This is a doubly useful approach in market examination for the regional companies, as it helps them see precisely what their field of operation needs, as far as their end users are concerned. Moreover, investors will be able to figure out which organization they can pay special attention to when attempting to extend their investments profiles. Additionally, the level of detail with which every segment and region is depicted can build this report up to be a convenient guide for them with regards to enhancing their place in a particular region or country, or with regards to entering new market fruitfully over the coming years.

The competitive analysis presented in the report on the 2012 2022 report on global crispr market competition status and forecast market size by players regions type application can be an imperative device in the overall arsenal that a market player possesses. A careful learning and understanding of the competitive profiles and the contentions between players is a crucial bit of data needed by all market players, and it is the thing that this report gives to every client. The level of customization for every player takes into consideration an extraordinary standpoint for them, taking into account significantly more noteworthy data.

Table of Contents

1. Executive Summary1
1.1 Methodology/Research Approach1
1.1.1 Research Programs/Design1
1.1.2 Market Size Estimation3
1.1.3 Market Breakdown and Data Triangulation4
1.2 Data Source5
1.2.1 Secondary Sources5
1.2.2 Primary Sources6
1.3 Disclaimer7
2. Market overview1
2.1 CRISPR Market overview1
2.2. Research and Development4
2.2.1. Scientific Papers Analysis4
2.2.2. Patent Analysis5
2.3. CRISPR vs. Conventional Gene Editing Tools6
2.4 CRISPR: Novel Initiatives8
2.4.1. CRISPR Cas9 Technology9
2.4.2. CRISPR as A Gene Editing Tool to Treat Genetic Disorders11
2.4.3. CRISPR as A Gene Editing Tool In Drug Development14
2.5 Industry Chain Analysis16
3. Sector Analysis18
3.1. Sector Overview18
3.1.1 Sector Overview of CRISPR18
3.1.2 Global Major Regions Status of CRISPR19
3.2 Sector Policy Analysis19
4 Global CRISPR Market Competition by Vendor22
5. Company Profiling23
5.1. Thermo Fisher Scientific (US)23
5.1.1. Company Basic Information23
5.1.2. Technology/Product Introduction23
5.1.3. Expenses, R&D Expenses and R&D Share23
5.2. Editas Medicine (US)24
5.2.1. Company Basic Information24
5.2.2. Technology/Product Introduction24
5.2.3. Expenses, R&D Expenses and R&D Share25
5.3. Caribou Biosciences (US)25
5.3.1. Company Basic Information25
5.3.2. Technology/Product Introduction26
5.3.3. Expenses, R&D Expenses and R&D Share26
5.4. CRISPR therapeutics (CH)26
5.4.1. Company Basic Information26
5.4.2. Technology/Product Introduction27
5.4.3. Expenses, R&D Expenses and R&D Share27
5.5. Intellia therapeutics, Inc. (US)27
5.5.1. Company Basic Information27
5.5.2. Technology/Product Introduction28
5.5.3. Expenses, R&D Expenses and R&D Share28
5.6. Cellectis (FR)28
5.6.1. Company Basic Information28
5.6.2. Technology/Product Introduction29
5.6.3. Expenses, R&D Expenses and R&D Share29
5.5. Horizon Discovery Plc (UK)30
5.8. Sigma Aldrich (US)30
5.9. Precision Biosciences (US)30
5.10. Genscript (US)30
5.11. Sangamo Biosciences Inc. (US)30
5.12. Lonza Group Limited (CH)30
5.13. Integrated DNA Technologies (US)30
5.14. New England Biolabs (US)30
5.15. Origene Technologies (US)30
5.16 Transposagen Biopharmaceuticals (US)30
5.17 Santa Cruz Biotechnology (US)30
5.18 Dharmacon (US)30
5.19 ZGene Biotech (TW)30
5.20 Blue Heron Bio (US)30
5.21 Takara Bio (JP)30
5.22 Synthego (US)30
5.23 Mirus Bio (US)31
5.24 Agilent Technologies (US)31
5.25 VCANBIO Cell & Gene Engineering (CN)31
5.26 Shenzhen Jinjia Group (CN)31
5.27 Galaxy Biomed (CN)31
5.28 Tofflon (CN)31
5.29 AOYANG Group (CN)31
5.30 ANKEBIO (CN)31
6. Geographical Analysis32
6.1. North America32
6.1.1. United States32
6.1.2. Canada32
6.1.3. RoNA (Rest of North America)32
6.2. Europe32
6.2.1. United Kingdom32
6.2.2. France32
6.2.3. Germany33
6.2.4. Spain33
6.2.5. Italy33
6.2.6. RoE (Rest of Europe)33
6.3. Asia Pacific33
6.3.1. China33
6.3.2. Japan33
6.3.3. India34
6.4. Rest of the World34
6.4.1. Middle East and Africa34
6.4.2. Latin America34
7. Market Determinants35
7.1. Drivers35
7.1.1. Rise in Drug Discovery Market35
7.1.2. Demand for Synthetic Genes36
7.1.3. High Prevalence of Genetic Birth Disorders38
7.1.4. Age Related Genetic Disorders42
7.1.5. Rise in the Healthcare Research and Development Budgets45
7.1.6. Venture Capital47
7.1.7. Global Increase in Lifestyle Oriented Diseases & Fatalities48
7.1.8. GMOS Increase Crop Yields and Promote Efficient Land Use48
7.2. Restraints51
7.2.1. Ethical Issues Related to Misuse of CRISPR Gene Editing Tool51
7.2.2. Limited Awareness55
7.2.3. Limited Presence in Emerging Markets55
7.3. Opportunities56
7.3.1. CRISPR Gene Editing Can Open the Market for Gene Surgery56
7.3.2. Emerging Contract Research Organization Market in Asia57
7.4. Challenges59
7.4.1. Patent Infringement59
7.4.2. Presence of Alternative Gene Editing Tools60
8. Market Segmentation63
8.1. by Application63
8.1.1. Genome Editing63
8.1.2. Genetic Engineering63
8.1.3. gRNA Database/Gene Library63
8.1.4. CRISPR Plasmid63
8.1.5. Human Stem Cells63
8.1.6. Genetically Modified Organisms/Crops64
8.1.7. Cell Line Engineering64
8.2. by End User64
8.2.1. Biotechnology Companies64
8.2.2. Pharmaceutical Companies64
8.2.3. Academic Institutes64
8.2.4. Research and Development Institutes65
8.3. Competitive Intelligence65
8.3.1. Merger and Acquisitions65
8.3.2. Innovation67
8.3.3. Venture Capital Funding70
9 Global CRISPR Market Forecast (2017-2022)71
9.1 Global CRISPR Market (Million USD) Forecast (2017-2022)71
9.2 Global Market (Million USD) Forecast by Regions (2017-2022)71
9.2.1 North America CRISPR Market (Million USD) Forecast (2017-2022)72
9.2.2 Europe CRISPR Market (Million USD) Forecast (2017-2022)72
9.2.3 Asia-Pacific CRISPR Market (Million USD) Forecast (2017-2022)72
9.3 Global CRISPR Market (Million USD) Forecast by Application (2017-2022)72
10 Strategic Recommendation and Conclusion74
11 Appendix75
Author List75

List of Tables and Figures


Table Research Programs/Design for This Report1
Figure Bottom-up and Top-down Approaches for This Report4
Figure Data Triangulation5
Table Key Data Information from Secondary Sources6
Table Key Data Information from Primary Sources7
Figure Brief History of CRISPR2
Figure CRISPR Prokaryotic Antiviral Defense Mechanism4
Table Global CRISPR Market 2014-2017 (Million US $)5
Figure Number of Scientific Papers and Growth Rate on CRISPR (2012-2016)5
Figure Number of Patents and Growth Rate on CRISPR (2012-2016)6
Figure Institution Authorized of CRISPR Patents by the United States and the EU6
Figure Representation of ZFNs, TALENs, and CRISPR/Cas97
Table Comparison between CRISPR, ZFN and TALENs7
Table Global Gene Editing Market Share by Editing Tool8
Figure A CRISPR Way to Fix Faulty Genes9
Figure Introduction of CRISPR/Cas910
Figure Cas9 in Vivo: Bacterial Adaptive Immunity11
Table Application Description of CRISPR Cas9 Technology11
Figure Gene Editing Using the CRISPR/Cas9 Technique12
Figure Genetic Disorders13
Figure Gene Editing with CRISPR15
Figure Selected Events and Discoveries Important for Functional Genomics for Drug MoA16
Figure CRISPR Industry Chain Analysis17
Table Global Major CRISPR Companies Involved In the Field Of Technology and Cooperation18
Table Global CRISPR Key Vendors19
Figure Global Market Share of CRISPR by Major Regions in 201620
Table Various Initiatives and Policies under Taken by the Government in Healthcare Sector20
Table Sector Policy Analysis20
Figure Researcher Examines a Pork Sample at the Cloning & Genetic Engineering Section of the Beijing Genomics Institute in China23
Figure Synthetic Gene Circuit24
Figure Genetic Birth Disorders26
Table Category of Genetic Diseases26
Table Age Related Genetic Disorders31
Figure the Impact of mTORC1 on Diseases of Ageing32
Table U.S. Department of Health & Human Services Budget (Million USD) Overview33
Figure Funding (Million USD) from National Natural Science Foundation of China and Growth Rate of CRISPR34
Figure Venture Capital35
Table Benefits of GM Crops36
Table Global Area of Genetic Modified Crop by Countries 1996 to 2015 (Million Hectares)37
Table Global Area of Genetic Modified Crop in 2014 and 2015: by Country (Million Hectares)38
Figure Regulatory Policies for Human Germ Cell Transformation in the World42
Figure Emerging Markets43
Figure Protocol for Gene Transfer to Joints45
Figure Early-phase CRISPR-Cas9 Platform Patent Control and Access47
Figure CRSIPR49
Figure ZFN49
Figure TALENs50
Figure CRISPR Market and Growth Rate by Genome Editing 2014-2017 ($ Million)51
Figure CRISPR Market and Growth Rate by Genetic Engineering 2014-2017 ($ Million)51
Figure CRISPR Market and Growth Rate by gRNA Database/Gene Library 2014-2017 ($ Million)51
Figure CRISPR Market and Growth Rate by CRISPR Plasmid 2014-2017 ($ Million)51
Figure CRISPR Market and Growth Rate by Human Stem Cells 2014-2017 ($ Million)51
Figure CRISPR Market and Growth Rate by Genetically Modified Organisms/Crops 2014-2017 ($ Million)52
Figure CRISPR Market and Growth Rate by Cell Line Engineering 2014-2017 ($ Million)52
Figure CRISPR Market and Growth Rate by Biotechnology Companies 2014-2017 ($ Million)52
Figure CRISPR Market and Growth Rate by Pharmaceutical Companies 2014-2017 ($ Million)52
Figure CRISPR Market and Growth Rate by Academic Institutes 2014-2017 ($ Million)52
Figure CRISPR Market and Growth Rate by Research and Development Institutes 2014-2017 ($ Million)53
Table Merger and Acquisitions53
Table Transaction Related to CRISPR Technology in 2014 to 201555
Table Innovation Status of Key Manufacturers55
Table Invested Amount ($ Million) of Leading Venture Capital Financed Biotechnology Companies58
Figure CRISPR Market and Growth Rate by United States 2014-2017 ($ Million)59
Figure CRISPR Market and Growth Rate by Canada 2014-2017 ($ Million)59
Figure CRISPR Market and Growth Rate by RoNA (Rest of North America) 2014-2017 ($ Million)59
Figure CRISPR Market and Growth Rate by United Kingdom 2014-2017 ($ Million)59
Figure CRISPR Market and Growth Rate by France 2014-2017 ($ Million)59
Figure CRISPR Market and Growth Rate by Germany 2014-2017 ($ Million)60
Figure CRISPR Market and Growth Rate by Spain 2014-2017 ($ Million)60
Figure CRISPR Market and Growth Rate by Italy 2014-2017 ($ Million)60
Figure CRISPR Market and Growth Rate by RoE (Rest of Europe) 2014-2017 ($ Million)60
Figure CRISPR Market and Growth Rate by China 2014-2017 ($ Million)60
Figure CRISPR Market and Growth Rate by Japan 2014-2017 ($ Million)60
Figure CRISPR Market and Growth Rate by India 2014-2017 ($ Million)61
Figure CRISPR Market and Growth Rate by Middle East and Africa 2014-2017 ($ Million)61
Figure CRISPR Market and Growth Rate by Latin America 2014-2017 ($ Million)61
Table Thermo Fisher Company Basic Information62
Table Technology/Product Introduction62
Table CRISPR Expenses (K USD), R&D Expenses (K USD) and R&D Share of Thermo Fisher Scientific 2014-201662
Figure CRISPR Expenses (K USD) and Growth Rate of Thermo Fisher Scientific 2014-201662
Figure CRISPR Expenses (K USD) and Total Expenses Share of Thermo Fisher Scientific 2014-201663
Table Editas Medicine Company Basic Information63
Table Pipeline of Editas Medicine63
Table CRISPR Expenses (K USD), R&D Expenses (K USD) and R&D Share of Editas Medicine 2014-201664
Figure CRISPR Expenses (K USD) and Growth Rate of Editas Medicine 2014-201664
Figure CRISPR Expenses (K USD) and Total Expenses Share of Editas Medicine 2014-201664
Table Caribou Biosciences Company Basic Information64
Table CRISPR Expenses (K USD), R&D Expenses (K USD) and R&D Share of Caribou Biosciences 2014-201665
Figure CRISPR Expenses (K USD) and Growth Rate of Caribou Biosciences 2014-201665
Figure CRISPR Expenses (K USD) and Total Expenses Share of Caribou Biosciences 2014-201665
Table CRISPR therapeutics Company Basic Information65
Table CRISPR Expenses (K USD), R&D Expenses (K USD) and R&D Share of CRISPR therapeutics 2014-201666
Figure CRISPR Expenses (K USD) and Growth Rate of CRISPR therapeutics 2014-201666
Figure CRISPR Expenses (K USD) and Total Expenses Share of CRISPR therapeutics 2014-201666
Table Intellia therapeutics, Inc. Company Basic Information66
Table CRISPR Expenses (K USD), R&D Expenses (K USD) and R&D Share of Intellia therapeutics, Inc. 2014-201667
Figure CRISPR Expenses (K USD) and Growth Rate of Intellia therapeutics, Inc. 2014-201667
Figure CRISPR Expenses (K USD) and Total Expenses Share of Intellia therapeutics, Inc. 2014-201667
Table Cellectis Company Basic Information67
Table CRISPR Expenses (K USD), R&D Expenses (K USD) and R&D Share of Cellectis 2014-201668
Figure CRISPR Expenses (K USD) and Growth Rate of Cellectis 2014-201668
Figure CRISPR Expenses (K USD) and Total Expenses Share of Cellectis 2014-201668

Request a Sample Copy

  • * :
  • * :
  • * :
  • * :
  • * :
  • :
  • * :
  • * indicates required field.

LATEST NEWS


Back To Top